Search for a trial

Prophylactic Cranial Irradiation (PCI) versus observation in radically treated patients with stage III non-small cell lung cancer: A phase III randomized study (NVALT-11/ DLCRG-02).

This randomized phase III study is designed to investigate whether PCI could reduce the incidence of brain metastases or delay their appearance in patients with stage III NSCLC who are treated with curative intention.

Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects with Previously Untreated Stage IV Squamous Non Small Cell Lung Cancer (NSCLC)

The purpose of this study is to find out if the combination of gemcitabine plus carboplatin and iniparib works better than gemcitabine and carboplatin alone in subjects with stage IV squamous non-small-cell lung cancer (NSCLC) that have not…

LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.

Run-in phase I: To confirm the safety and tolerability of BIBF 1120 up to a dose level of 200 mg b.i.d added to a standard dose of cisplatin/gemcitabine in first line NSCLC patients with squamous cell histology. Pharmacokinetics of BIBF 1120 and…

Randomized trial on chest irradiation in extensive disease small cell lung cancer

to evaluate the role of thoracic irradiation in patients with ED-SCLC who respond to chemotherapy and to assess the effect on 1 year survival

PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC;LYMPHOMA KINASE (ALK) GENE LOCUS

To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy, pemetrexed/cisplatin or pemetrexed/carboplatin (Arm B), in prolonging PFS in patients with advanced non-squamous NSCLC whose tumors harbor a translocation or inversion…

Longitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients

• To study the effect of treatment modalities immunotherapy (anti-PD1 or anti-PDL-1), and targeted therapy (crizotinib, gefitinib or erlotinib) on the size and diversity of lung carcinoma-specific T cell populations as measured by immune assays,…

An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations

To determine long-term outcome of patients with advanced non-squamous NSCLC harbouring at diagnosis EGFR mutations with and without T790M mutation and treated with the combination of erlotinib and bevacizumab.

Recovery of Physical and Psychological health, and Health-Related Quality of Life (HRQoL) in lung cancer patients six months following lung resection.

The main aim of this study is to explore the recovery of physical and psychological health status, and HRQoL simultaneously in lung cancer patients that have undergone lung resection in the Netherlands. Next to that, we hope to identify the…

Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial

To evaluate the efficacy of the drug combination. Translational work is aimed to explore pharmacodynamic, predictive and surrogate endpoint biomarkers in tumor tissue and blood.

A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib

The primary objective of this study is to evaluate the overall response rate (ORR) of LY2875358 plus erlotinib therapy and LY2875358 monotherapy in patients with met proto-oncogene (hepatocyte growth factor receptor) (MET) diagnostic positive (MET…

ACOSOG Z4099/ RTOG 1021 A randomized phase III study of sublobular resection (+/- brachytherapy) versus stereotactic body radiation therapy in high risk patients with stage I non-small cel lung cancer (NSCLC)

This study is important in that not only will we learn information about the true oncologic differences between these therapies, we will also determine the relative impact of these therapies on pulmonary function and quality of life.

High-dose, pulsatile erlotinib after progression on standard dose erlotinib in EGFR-mutated NSCLC patients

see whether this treatment schedule is effective in EGFR-mutated NSCLC patients who have developed progression after treatment with EGFR-TKI monotherapy in standard dose before

A phase II study of gefitinib and fulvestrant in patients with advanced EGFR mutated non small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitors

2.1 Primary objectiveTo assess the rate of no progression (NPR) at 8 weeks following treatment with the combination of gefitinib and fulvestrant in EGFR mutated patients who failed previous treatment with reversible EGFR TKI*s (gefitinib or…

A phase II, multi-center, open-label study of AUY922 administered i.v. on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemotherapy

Primary objective* To estimate efficacy for each study stratum at 18 weeks as assessed by RECISTKey Secondary objectives:* To estimate overall survival (OS) and progression free survival (PFS) in patients with advanced NSCLC* To determine safety and…

A phase II study of sorafenib and metformin in patients with locally advanced and/or metastatic non-smal cell lung cancer (NSCLC) with a K-Ras mutation

To assess the efficacy of combined treatment with sorafenib and metformin.

Quantification of mediastinal lymph node position variability by implanted fiducial markers using Cone Beam CT in Non-Small Cell Lung Cancer patients treated with radical irradiation

Hypothesis: Fiducial markers implanted in mediastinal lymph nodes by EUS-FNA or EBUS will show inter and intra-fraction lymph node position variability on 4D-(CB) CT-scansObjective: To quantify respiratory induced mediastinal lymph node motion and…

Phase I Hybrid study: combined stereotactic radiotherapy and conventional fractionation in stage II and III non small cell lung cancer with peripheral tumors smaller than 5 cm

To define the recommended phase II mean*lung dose (MLD) to treat peripheral stage II or III NSCLC using SABR for the primary tumor and CFRT for the mediastinal lymph nodes while given concurrent chemotherapy.

Cost-effectiveness of a stepped care strategy to improve symptoms of depression or anxiety in patients treated for head and neck cancer or lung cancer.

To evaluate cost-effectiveness of a stepped care strategy to improve symptoms of depression or anxiety in patients treated for head and neck cancer or lung cancer.

Sorafenib pharmacokinetics in non small cell lung cancer patients: an in;vivo study using positron emission tomography

To assess sorafenib pharmacokinetics and biodistribution, K-Ras mutational status, tumor uptake and tumor response in NSCLC patients.

Optimising Photodynamic Therapy for the Treatment of Head and Neck Cancer

The main objective of the study is to monitor the factors effecting success of PDT, namely oxygen, photosensitizer concentration and, light dose before and during illumination to gather data that can be clinically correlated and later implemented.